Overview

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

Status:
RECRUITING
Trial end date:
2030-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
Phase:
PHASE1
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.